U.S. Markets open in 6 hrs 42 mins

Aethlon Medical Announces Fiscal 2018 Second Quarter Results

SAN DIEGO, Nov. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal second quarter ended September 30, 2017.

Key Recent Developments

EAP – In September 2017, the United States Food and Drug Administration (FDA) granted an Expedited Access Pathway (EAP) designation to the Company to support the advancement of the Aethlon Hemopurifier® to treat life-threatening viruses. On October 25, 2017, the FDA published guidance that indicates the Hemopurifier and other EAP devices will now be advanced under a "Breakthrough Device" designation, which FDA is establishing as a result of the 21st Century Cures Act that was signed into law on December 13, 2016. The FDA Breakthrough Device designation was established to facilitate more rapid patient access to breakthrough technologies with the potential to address life threatening disease conditions for which no approved or cleared treatment alternatives exist.

The FDA agreed to the following "indication for use" in its EAP submission; "The Hemopurifier is a single-use device indicated for the treatment of life-threatening highly glycosylated viruses that are not addressed with an approved treatment." 

NCI Contract -- In September 2017, the National Cancer Institute (NCI) has awarded the Company a government contract. The title of the SBIR Topic 359 Phase I contract is "Device Strategy for Selective Isolation of Oncosomes and Non-Malignant Exosomes."  The NCI Phase I contract period runs from September 15, 2017 through June 14, 2018.  The total amount of the firm fixed price contract is $299,250

Public Offering -- In October 2017, the Company completed a public offering of common stock and warrants that raised net proceeds of $5,289,735. Additionally, during the September quarter, the Company raised $1,648,411 in net proceeds from sales under its At the Market offering facility.

Financial Results

The net loss for the September 2017 quarter was $1.3 million, or $0.14 per share, compared to a net loss for the September 2016 quarter of $2.3 million, or $0.29 per share.

Consolidated operating expenses were $1.24 million in the September 2017 quarter compared to $2.61 million in the September 2016 quarter, a decrease of approximately $1.37 million. This decrease was due to a reduction in payroll and related expenses of approximately $1.19 million, a decrease in professional fees of approximately $128,000 and a reduction in general and administrative expenses of approximately $55,000.

The $1.19 million decrease in payroll and related expenses was primarily due to a $1.24 million decrease in stock-based compensation. The decrease in stock-based compensation was due to the upfront vesting percentage of the RSU grants to our officers and directors in August 2016. The cash-based payroll and related expenses increased by approximately $45,000 due to headcount additions in our scientific staff.

The Company had other expense of approximately $72,000 in the September 2017 quarter compared to approximately $37,000 in the September 2016 quarter, an increase of approximately $35,000

At September 30, 2017, the Company had a cash balance of approximately $920,000. In October 2017, the Company completed a public offering that raised net proceeds of approximately $5.3 million.

The unaudited condensed consolidated balance sheet for September 30, 2017 and the unaudited condensed consolidated statements of operations for the quarters and six month periods ended September 30, 2017 and 2016 follow at the end of this release.

Conference Call

Aethlon will hold a conference call for investors on Thursday, November 2, 2017 at 1:30 p.m. PT (4:30 p.m. ET). To listen to the call by phone, interested parties within the U.S. should call 1-844-836-8741 and international callers should call 1-412-317-5442. All callers should ask for the Aethlon Medical Inc., conference call. The conference call will also be available through a live webcast at www.aethlonmedical.com. Details for the webcast may be found on the Company's IR events page at http://ir.aethlonmedical.com.

A replay of the call will be available approximately one hour after the end of the call through November 9, 2017. The replay can be accessed via Aethlon Medical's website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada Toll Free at 1-855-669-9658. The replay conference ID number is 10114031.

About Aethlon Medical, Inc.

Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections.  The United States Food and Drug Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of life-threatening viruses that are not addressed with approved therapies.

In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the Hemopurifier® to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic viruses.  Based on its use to treat Ebola virus, the Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine.

Aethlon is also investigating the potential therapeutic use of the Hemopurifier® to reduce the presence of tumor-derived exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients.  Additionally, Aethlon is the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).  Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.  You can also connect with us on Twitter, LinkedIn, Facebook and Google+.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Forward-looking statement includes statements relating to the public offering and the satisfaction of closing conditions relating to the public offering, as well as general economic and market factors. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2017, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 extension 3300
Jfrakes@aethlonmedical.com

Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com

AETHLON MEDICAL, INC.

Condensed Consolidated Balance Sheet











ASSETS



September 30, 2017


March 31, 2017



(unaudited)


(unaudited)

CURRENT ASSETS





Cash

$920,072


$1,559,701


Prepaid expenses

91,737


37,551






TOTAL CURRENT ASSETS

1,011,809


1,597,252







Property and equipment, net

38,858


29,223


Patents, net

80,414


84,996


Other assets

14,897


14,897






TOTAL NONCURRENT ASSETS

134,169


129,116







TOTAL ASSETS

$1,145,978


$1,726,368











LIABILITIES AND STOCKHOLDERS' EQUITY






CURRENT LIABILITIES





Accounts payable 

275,579


484,423


Due to related parties

48,616


57,866


Other current liabilities

21,743


69,467






TOTAL CURRENT LIABILITIES

345,938


611,756






NONCURRENT LIABILITIES





Convertible notes payable, non-current portion, net

780,579


519,200

TOTAL NONCURRENT LIABILITIES

780,579


519,200






TOTAL LIABILITIES

1,126,517


1,130,956






COMMITMENTS AND CONTINGENCIES









STOCKHOLDERS' EQUITY










Common stock, par value of $0.001, 30,000,000 shares authorized; 9,618,909 and 8,797,086 shares issued and outstanding as of September 30, 2017 and March 31, 2017, respectively

9,618


8,796


Additional paid-in capital

97,023,094


94,445,739


Accumulated deficit

(96,923,845)


(93,778,156)






TOTAL STOCKHOLDERS' (DEFICIT) EQUITY BEFORE NONCONTROLLING INTERESTS

108,867


676,379






Noncontrolling interests

(89,406)


(80,967)






TOTAL STOCKHOLDERS' (DEFICIT) EQUITY

19,461


595,412







TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY

$1,145,978


$1,726,368






 

AETHLON MEDICAL, INC.

Condensed Consolidated Statements of Operations

For the three and month periods ended September 30, 2017 and 2016










Three Months


Three Months


Six Months


Six Months


Ended 9/30/17


Ended 9/30/16


Ended 9/30/17


Ended 9/30/16


(unaudited)


(unaudited)


(unaudited)


(unaudited)









Government contract income

$                     -


$         387,438


$                     -


$         392,073

  Total revenues

-


387,438


-


392,073









OPERATING EXPENSES








Professional fees

383,178


510,982


726,201


1,078,731

Payroll and related

618,081


1,813,003


1,248,308


2,158,190

General and administrative

234,914


290,131


421,913


513,681

  Total operating expenses

1,236,173


2,614,116


2,396,422


3,750,602









OPERATING LOSS

(1,236,173)


(2,226,678)


(2,396,422)


(3,358,529)









OTHER (INCOME) EXPENSE








Loss on share for warrant exchanges

10,425


-


130,214


-

Loss on debt extinguishment

-


-


376,909


616,889

Warrant repricing expense

-


-


-


345,841

Interest and other debt expenses

61,979


36,576


250,583


78,743


72,404


36,576


757,706


1,041,473









NET LOSS BEFORE NONCONTROLLING INTERESTS

$(1,308,577)


$(2,263,254)


$(3,154,128)


$(4,400,002)









Loss attributable to noncontrolling interests

(4,671)


(7,668)


(8,439)


(15,400)









NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS

$(1,303,906)


$(2,255,586)


$(3,145,689)


$(4,384,602)









Basic and diluted net loss available to 








  common stockholders per share

$          (0.14)


$          (0.29)


$          (0.35)


$          (0.57)









Weighted average number of common








  shares outstanding

9,032,157


7,756,883


8,939,624


7,690,369









 

View original content:http://www.prnewswire.com/news-releases/aethlon-medical-announces-fiscal-2018-second-quarter-results-300548026.html

  • Finance
    CNBC

    Morgan Stanley: The stock sell-off is going to get worse

    The stock market is in the middle of a rolling bear market, says Morgan Stanley's Mike Wilson. "It's being caused by a drain in liquidity and peaking growth," Wilson says. The stock market sell-off is only going to get worse, predicts Morgan Stanley's chief U.S. equity strategist, Mike Wilson.

  • Why New Age Beverage Corp. Stock Popped Today
    Business
    Motley Fool

    Why New Age Beverage Corp. Stock Popped Today

    Shares of New Age Beverage Corp. (NASDAQ: NBEV) were climbing again today, riding a surge on marijuana stocks as growers like Tilray, Cronos Group, and Canopy Growth all jumped by double digits. Along with the bullish sentiment in the industry, a number of other factors seemed to be driving New Age shares higher, including the recent hiring of a new CFO, the upcoming legalization of recreational marijuana in Canada on Wednesday, and the market's reaction to its launch last week of a new line of beverages infused with cannabidiol (CBD). On Friday, New Age named Gregory Gould as its new CFO, a notable move as Gould brings experience from the pharmaceutical industry, which should help the beverage company as it moves into CBD products.

  • Sears bankruptcy could make these 5 big companies multi-million-dollar losers
    Finance
    Yahoo Finance

    Sears bankruptcy could make these 5 big companies multi-million-dollar losers

    Being an unsecured creditor of Sears (SHLD) right now is not a good place to be. The 125-year old former retail icon filed for chapter 11 bankruptcy protection early on Monday, crippled from years of losses and mounting debt. Sears plans to close about

  • Brits Are All Making the Same Joke About the New Royal Baby
    News
    Time

    Brits Are All Making the Same Joke About the New Royal Baby

    Meghan Markle, the Duchess of Sussex, is expecting her first child with Prince Harry. The news, announced Monday morning by Kensington Palace, has already been greeted by hundreds of messages of congratulations for the royal couple on social media. The U.K. is set to leave the European Union on March 29, exactly two years after Prime Minister Theresa May started the formal process for doing so by invoking Article 50 of the Lisbon Treaty.

  • Jamal Khashoggi was accidentally killed during interrogation: report
    World
    Fox Business Videos

    Jamal Khashoggi was accidentally killed during interrogation: report

    Fox Business foreign policy analyst Walid Phares on the report that Saudi journalist Jamal Khashoggi was accidentally killed.

  • Why Marijuana Stocks Canopy Growth, Cronos Group, and Tilray Crushed It Today
    Business
    Motley Fool

    Why Marijuana Stocks Canopy Growth, Cronos Group, and Tilray Crushed It Today

    The three Canadian marijuana stocks that currently trade on major U.S. stock exchanges enjoyed big gains on Monday. Shares of Canopy Growth (NYSE: CGC) were up 14% as of 3:48 p.m. EDT, while Cronos Group (NASDAQ: CRON) and Tilray (NASDAQ: TLRY) jumped 18.9% and 12.1%, respectively. Two of the three marijuana growers reported new developments earlier in the day.

  • These are the bad things about early retirement that no one talks about
    News
    MarketWatch

    These are the bad things about early retirement that no one talks about

    For all the glamour of living an early retirement lifestyle, there are plenty of negatives I’ve come to discover since I permanently left my job in 2012. As a result, you’re repeatedly forced to will yourself into action.

  • Elizabeth Warren Calls on Trump to Pay $1 Million After Releasing DNA Test
    Politics
    Fortune

    Elizabeth Warren Calls on Trump to Pay $1 Million After Releasing DNA Test

    Elizabeth Warren is ready for her pay day. The senator from Massachusetts took to Twitter Monday morning, calling on President Donald Trump to cough up the $1 million he promised if she proved she had Native American heritage.

  • As Cannabis D-Day Approaches, Winners and Losers Set to Emerge
    Business
    Bloomberg

    As Cannabis D-Day Approaches, Winners and Losers Set to Emerge

    After Canada legalizes recreational marijuana on Oct. 17, it will only take a quarter or two for clear winners and losers to emerge, according to investors and analysts who follow the sector. “These have all been concept stocks and they’re going to actually have to be real companies in another few months, which I think a lot of guys are terrified about,” said Greg Taylor, who manages the Purpose Marijuana Opportunities Fund. Taylor prefers CannTrust Holdings Inc., Hexo Corp. and Organigram Holdings Inc., which he says trade at a “more realistic valuation” than some of their bigger peers.

  • 2 Hot Marijuana Stocks Listing Soon on U.S. Exchanges -- Are They Buys?
    Business
    Motley Fool

    2 Hot Marijuana Stocks Listing Soon on U.S. Exchanges -- Are They Buys?

    Two marijuana stocks that are currently listed on Canadian stock exchanges soon plan also to list on U.S. stock exchanges. Aurora Cannabis (NASDAQOTH: ACBFF) (TSX: ACB) expects to trade on the New York Stock Exchange (NYSE) by the end of October and Aleafia Health (NASDAQOTH: ALEAF) should soon trade on the Nasdaq stock exchange. Are these hot marijuana stocks that are coming soon to U.S. stock exchanges smart picks to buy now?

  • After years of wasting time in meetings, 3 former Googlers decided to do things differently at their new startup
    Business
    Business Insider

    After years of wasting time in meetings, 3 former Googlers decided to do things differently at their new startup

    The executives of the startup Beeswax, all former Google execs, say they've learned how to keep meetings streamlined and efficient. The three founders of the ad-tech startup Beeswax seem to get that. "We're all thoughtful about not having a proliferation of meetings, because one thing we all felt in our previous careers is that there can be lots of redundant meetings," Shamim Samadi, Beeswax's chief product officer, told Business Insider.

  • Finance
    TheStreet.com

    Monday Madness: Is Nvidia a Hit or Miss?

    TheStreet's Julie Iannuzzi covered Jim Cramer's investing boot camp. Nvidia (NVDA - Get Report) has long been a favorite of TheStreet's founder and Action Alerts Plus Portfolio Manager Jim Cramer, but he told a packed audience Saturday at his Boot Camp for Investors in New York why his charitable trust recently sold out of the stock.

  • Business
    TheStreet.com

    Canopy Growth Is Poised to Explode to the Upside

    Shares of Canopy have soared 68% over the past three months. In this daily bar chart of CGC, below, we can see that prices are up five-fold over the past 12 months. CGC was trading at $10 back last October and now is trading around $50 with spikes above $55 last month.

  • Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla
    Business
    MarketWatch

    Marijuana stocks to watch: Canopy Growth is the cannabis business’s $4 billion gorilla

    The following article is part of a package of stories that MarketWatch is publishing to mark the start of full legalization of cannabis for adult use in Canada on Wednesday. Smith Falls, Ontario–based Canopy Growth Corp. made headlines and drove cannabis stocks to new heights over the summer when it announced that Corona brewer Constellation Brands Inc. was going to invest an additional $4 billion in the company. Billed by both companies as a strategic partnership, the additional $4 billion investment adds to the 9.9% stake that Constellation bought in October of last year and sets the company up to either be bought outright by Constellation — via warrants that could increase its stake to more than 50% — or continue to work with the beverage company to create a range of consumer-focused cannabis products that may one day appear in markets in dozens of countries.

  • Saudi Arabia Breaks 45-Year Taboo With Veiled Threat to Use Oil as a Weapon
    World
    Bloomberg

    Saudi Arabia Breaks 45-Year Taboo With Veiled Threat to Use Oil as a Weapon

    While few think that Saudi Arabia is prepared to follow through, even the suggestion of using oil as a weapon undermines Riyadh’s long-standing effort to project itself as a force for economic stability. The anxieties were exacerbated by an opinion piece penned by Turki Al Dakhil, who heads the state-owned Arabiya news network and is close to the Royal Court, in which he openly talked about using oil as a weapon.

  • This Is the Average American's Salary. How Does Yours Compare?
    Business
    Motley Fool

    This Is the Average American's Salary. How Does Yours Compare?

    In an age of oversharing, many of us are remarkably tight-lipped when it comes to talking salary. But in reality, knowing where you stand can help you determine whether you're in a good place or whether you should be taking steps to boost your earnings

  • Goldman Sachs and Raymond James cut Netflix price target ahead of earnings
    Business
    Yahoo Finance Video

    Goldman Sachs and Raymond James cut Netflix price target ahead of earnings

    Netflix getting its price target slashed by both Goldman Sachs and Raymond James ahead of its highly expected earnings report tomorrow. Both firms are concerned that rising interest rates could pinch the company’s valuation.

  • Many U.S. mall owners say good riddance to Sears
    Finance
    Reuters

    Many U.S. mall owners say good riddance to Sears

    The real estate investment trusts that own the malls and shopping centers where many Sears stores are anchor tenants have waited years for the retailer's demise to renovate the sites and boost rent, although redevelopment costs may strain some plans. Most large U.S. malls are controlled by REITs. In recent years, the REITs have cut their exposure to Sears Holdings Corp, which filed for Chapter 11 bankruptcy on Monday.

  • Warren Buffett predicted the fall of Eddie Lampert and Sears over 10 years ago (SHLD, BRK.A, BRK.B)
    Finance
    Business Insider

    Warren Buffett predicted the fall of Eddie Lampert and Sears over 10 years ago (SHLD, BRK.A, BRK.B)

    Sears filed for Chapter 11 bankruptcy early Monday, the culmination of a downward spiral. CEO Eddie Lampert, once called the "next Warren Buffett," will also step down. Incidentally, Buffett predicted the retailer's and Lampert's downfall in 2005.

  • Better Marijuana Stock: Aurora Cannabis vs. Auxly Cannabis Group
    Business
    Motley Fool

    Better Marijuana Stock: Aurora Cannabis vs. Auxly Cannabis Group

    One is market cap: Aurora's market cap is nearly 18 times bigger than Auxly's. Then there's stock performance. Here's how Aurora Cannabis and Auxly Cannabis Group stack up against each other in the areas that do matter.

  • Why Marijuana Stocks Cronos Group, Canopy Growth, and Tilray Jumped Today
    Business
    Motley Fool

    Why Marijuana Stocks Cronos Group, Canopy Growth, and Tilray Jumped Today

    The stock market pulled back on Monday, with major benchmarks failing to build on the positive momentum from last Friday. Cronos Group (NASDAQ: CRON), Canopy Growth (NYSE: CGC), and Tilray (NASDAQ: TLRY) were among the best performers. All three of these stocks have something in common: They all stand to benefit from Wednesday's effective date for legal sales of recreational cannabis product in Canada.

  • Finance
    TheStreet.com

    General Electric Slips as Cowen Suggests Culp Needs to Take Action

    fell Monday after Cowen and Co. cut its price target on the stock as analysts expect the new Chief Executive Larry Culp to take actions to improve the beleaguered industrial's financial standing. Cowen analysts, including Gautam Khanna, said they expect Culp to impose a dividend cut, possibly raise more equity, and reset earnings per share/free cash flow, to shore up the balance sheet.

  • Here’s How Prince Harry and Meghan Markle’s Baby Will Change the Line Of Succession
    News
    Time

    Here’s How Prince Harry and Meghan Markle’s Baby Will Change the Line Of Succession

    Prince Harry and Meghan Markle are expecting a baby in spring 2019, Kensington Palace announced Monday morning. Harry and Meghan married in May, becoming the Duke and Duchess of Sussex. Now, the question is where the new arrival will fit into the line of succession of the British royal family.

  • Lands’ End shares sink after Sears bankruptcy announcement
    Business
    American City Business Journals

    Lands’ End shares sink after Sears bankruptcy announcement

    Shares of Lands’ End Inc. declined more than 4 percent Monday on the same day that its longtime retail partner Sears Holdings Corp. declared Chapter 11. Hoffman Estates, Illinois-based Sears (Nasdaq: SHLD) filed for bankruptcy protection on Monday and announced plans to close another 142 stores across the country. The closures, as well as the hundreds of stores that Sears has shuttered previously, impact Lands’ End because the Dodgeville-based casual apparel company operates Lands’ End shops at Sears stores across the shrinking chain.

  • The Worst Mistake Tilray Investors Can Make Right Now
    Business
    Motley Fool

    The Worst Mistake Tilray Investors Can Make Right Now

    Tilray (NASDAQ: TLRY) investors have certainly seen plenty of opportunities to mess up lately, especially with the stock experiencing huge swings both up and down on a frequent basis. When Tilray conducted its initial public offering (IPO) back in July 2018, the company immediately became the third-largest Canadian marijuana stock in terms of market cap. Although Canopy briefly regained its mantle as the marijuana stock with the greatest market cap, Tilray is again on top.